{"id":"NCT01657019","sponsor":"Shire","briefTitle":"Open Label Extension in Adults With Binge Eating Disorder (BED)","officialTitle":"A Phase 3, Multicenter, Open-label, 12 Month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults With Binge Eating Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-08-21","primaryCompletion":"2014-10-21","completion":"2014-10-21","firstPosted":"2012-08-03","resultsPosted":"2015-12-15","lastUpdate":"2021-06-09"},"enrollment":604,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Binge Eating Disorder"],"interventions":[{"type":"DRUG","name":"Lisdexamfetamine dimesylate","otherNames":["Vyvanse","SPD489","LDX"]}],"arms":[{"label":"Lisdexamfetamine dimesylate","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety and tolerability of SPD489 administered as a daily morning dose (50 or 70mg) in the treatment of moderate to severe binge eating disorder (BED) in adults","primaryOutcome":{"measure":"Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) as a Measure of Safety","timeFrame":"52 weeks","effectByArm":[{"arm":"All Participants","deltaMin":84.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":89,"countries":["United States","Germany","Spain"]},"refs":{"pmids":["28383364"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":599},"commonTop":["Dry mouth","Headache","Insomnia","Upper respiratory tract infection","Nasopharyngitis"]}}